The new generation of cancer treatments

Cantargia's CAN04 antibody treatment fights cancer by activating the immune system, and by blocking signals that lead to tumour growth.

Read more

Cantargia Team – passion for innovation and results

Read more

Development of new antibody-based cancer treatments

Read more

Latest press releases

Cantargia strengthens organisation with CFO

Cantargia publishes interim report for January-March 2017

Cantargia’s application to investigate the antibody product candidate CAN04 in the CANFOUR phase I/IIa clinical trial has been submitted

Cantargia is a biotechnology company specialising in dual-action antibody-based cancer treatments. CAN04, the company's patented antibody treatment, has a dual-action and fights cancer by activating the immune system and by blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immunoncology.

Compared to similar treatments, Cantargias candidate CAN04 seems to offer a broader variety of treatment mechanisms towards the cancer".

SMALLCAP, Analys Anders Eriksson & Niklas Elmhammer, 2015-12-03

We estimate that the company has a good chance to reach their goal considering CAN04's unique target molecule and promising basic research".

REDEYE, Analysis 2016-10-07

How CAN04 attacks a cancer tumour

Watch the animated video

Press releases
Show more press releases  >>